Clinical Trials Browser

Withdrawn × Gemcitabine × Clear all

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06498518 2025-07-11

PRIMUS006

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03541486 2025-03-10

XACT-PANC-2

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02428764 2024-12-10

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Phase 2 Withdrawn

Lung Neoplasms

NCT04183062 2024-11-08

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Phase 2 Withdrawn

Bone Neoplasms, Sarcoma

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06370871 2024-07-17

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Phase 3 Withdrawn

Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT06017323 2023-10-25

ProglumidePanc

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05251038 2023-05-11

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT01971489 2023-04-27

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT04546828 2022-06-15

A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT05212025 2022-06-14

Adavosertib and Gemcitabine in Advanced Pancreatic

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT04480190 2022-04-20

Neoadjuvant Therapy in Biliary Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05116800 2021-12-07

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoma, B-Cell

NCT04906876 2021-07-28

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04230330 2020-11-05

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Extranodal NK-T-Cell

NCT00226746 2020-09-18

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT03579758 2020-06-05

Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer

Phase 3 Withdrawn

Gastrointestinal

Gallbladder Neoplasms

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT00728000 2019-11-25

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT03697239 2019-06-11

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT02527772 2019-06-04

LD-FOX4/HCC

Phase 2/3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT02534337 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Phase 2/3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03797443 2019-05-31

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03908333 2019-05-30

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03392571 2019-05-07

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Phase 2 Withdrawn

Gastrointestinal

Resectable Pancreatic Cancer

NCT02105350 2018-02-19

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Phase 1 Withdrawn

Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Recurrence

NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Phase NA Withdrawn

Infiltrating Bladder Urothelial Carcinoma

NCT02405910 2017-11-06

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02723838 2017-03-07

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Phase 1 Withdrawn

Neoplasms

NCT00881387 2016-12-15

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma

NCT01702714 2016-11-04

A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease

Phase 1 Withdrawn

Non-Squamous Non-Small Cell Lung Cancer

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02701673 2016-05-04

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Phase 1/2 Withdrawn

Lymphoma

NCT02537561 2016-02-11

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00469976 2015-10-08

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01598584 2015-09-28

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Phase 2/3 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Phase 2 Withdrawn

Neoplasms, Unknown Primary

NCT02159248 2015-04-28

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms